JP2024503698A5 - - Google Patents
Info
- Publication number
- JP2024503698A5 JP2024503698A5 JP2023543034A JP2023543034A JP2024503698A5 JP 2024503698 A5 JP2024503698 A5 JP 2024503698A5 JP 2023543034 A JP2023543034 A JP 2023543034A JP 2023543034 A JP2023543034 A JP 2023543034A JP 2024503698 A5 JP2024503698 A5 JP 2024503698A5
- Authority
- JP
- Japan
- Prior art keywords
- rbm
- fusion protein
- vaccine according
- cov
- sars
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163138228P | 2021-01-15 | 2021-01-15 | |
| US63/138,228 | 2021-01-15 | ||
| US202163140921P | 2021-01-24 | 2021-01-24 | |
| US63/140,921 | 2021-01-24 | ||
| US202163161439P | 2021-03-15 | 2021-03-15 | |
| US63/161,439 | 2021-03-15 | ||
| US202163173972P | 2021-04-12 | 2021-04-12 | |
| US63/173,972 | 2021-04-12 | ||
| US202163193558P | 2021-05-26 | 2021-05-26 | |
| US63/193,558 | 2021-05-26 | ||
| US202163222930P | 2021-07-16 | 2021-07-16 | |
| US63/222,930 | 2021-07-16 | ||
| US202163241944P | 2021-09-08 | 2021-09-08 | |
| US63/241,944 | 2021-09-08 | ||
| US202163283795P | 2021-11-29 | 2021-11-29 | |
| US63/283,795 | 2021-11-29 | ||
| US202163284565P | 2021-11-30 | 2021-11-30 | |
| US63/284,565 | 2021-11-30 | ||
| PCT/US2022/012607 WO2022155524A1 (en) | 2021-01-15 | 2022-01-14 | Variant strain-based coronavirus vaccines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024503698A JP2024503698A (ja) | 2024-01-26 |
| JP2024503698A5 true JP2024503698A5 (https=) | 2025-04-14 |
Family
ID=80222159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023543034A Pending JP2024503698A (ja) | 2021-01-15 | 2022-01-14 | 変異型株ベースのコロナウイルスワクチン |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240100151A1 (https=) |
| EP (1) | EP4277655A1 (https=) |
| JP (1) | JP2024503698A (https=) |
| AU (1) | AU2022208057A1 (https=) |
| CA (1) | CA3208486A1 (https=) |
| WO (1) | WO2022155524A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL4023249T3 (pl) | 2014-04-23 | 2025-03-10 | Modernatx, Inc. | Szczepionki z kwasem nukleinowym |
| MA42543A (fr) | 2015-07-30 | 2018-06-06 | Modernatx Inc | Arn épitope peptidiques concatémériques |
| US11564893B2 (en) | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| EP4011451A1 (en) | 2015-10-22 | 2022-06-15 | ModernaTX, Inc. | Metapneumovirus mrna vaccines |
| AU2016341309A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Cancer vaccines |
| WO2017201342A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding jagged1 for the treatment of alagille syndrome |
| CA3036831A1 (en) | 2016-09-14 | 2018-03-22 | Modernatx, Inc. | High purity rna compositions and methods for preparation thereof |
| MA46766A (fr) | 2016-11-11 | 2019-09-18 | Modernatx Inc | Vaccin antigrippal |
| WO2018170256A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Herpes simplex virus vaccine |
| WO2018170245A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| US11905525B2 (en) | 2017-04-05 | 2024-02-20 | Modernatx, Inc. | Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
| MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
| WO2019036682A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | RNA VARIANTS POLYMERASE |
| MA49914A (fr) | 2017-08-18 | 2021-04-21 | Modernatx Inc | Procédés analytiques par hplc |
| EP3675817A1 (en) | 2017-08-31 | 2020-07-08 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| EP3746090A4 (en) | 2018-01-29 | 2021-11-17 | ModernaTX, Inc. | RSV RNA Vaccines |
| WO2020061295A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| CA3113025A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Peg lipids and uses thereof |
| WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| AU2020224103A1 (en) | 2019-02-20 | 2021-09-16 | Modernatx, Inc. | Rna polymerase variants for co-transcriptional capping |
| CN113874502A (zh) | 2019-03-11 | 2021-12-31 | 摩登纳特斯有限公司 | 补料分批体外转录方法 |
| US12070495B2 (en) | 2019-03-15 | 2024-08-27 | Modernatx, Inc. | HIV RNA vaccines |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| CN113684219B (zh) * | 2020-05-18 | 2022-12-23 | 康希诺(上海)生物科技有限公司 | mRNA或mRNA组合物及其制备方法和应用 |
| US11918643B2 (en) | 2020-12-22 | 2024-03-05 | CureVac SE | RNA vaccine against SARS-CoV-2 variants |
| EP4274607A1 (en) | 2021-01-11 | 2023-11-15 | ModernaTX, Inc. | Seasonal rna influenza virus vaccines |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| US20240382581A1 (en) * | 2021-07-09 | 2024-11-21 | Modernatx, Inc. | Pan-human coronavirus vaccines |
| US12397051B2 (en) * | 2021-09-14 | 2025-08-26 | Globe Biotech Limited | Vaccine for use against coronavirus and variants thereof |
| WO2023092069A1 (en) * | 2021-11-18 | 2023-05-25 | Modernatx, Inc. | Sars-cov-2 mrna domain vaccines and methods of use |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| US12529047B1 (en) | 2021-12-21 | 2026-01-20 | Modernatx, Inc. | mRNA quantification methods |
| JP2025529906A (ja) * | 2022-08-22 | 2025-09-09 | ザ ヘンリー エム ジャクソン ファンデイション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド | コロナウイルスに対するワクチン |
| EP4608442A1 (en) | 2022-10-28 | 2025-09-03 | GlaxoSmithKline Biologicals S.A. | Nucleic acid based vaccine |
| WO2025166202A1 (en) | 2024-01-31 | 2025-08-07 | Modernatx, Inc. | Lipid nanoparticle compositions comprising sialic acid derivatives and the uses thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2340499T3 (es) | 2001-06-05 | 2010-06-04 | Curevac Gmbh | Arnm de antigeno tumoral estabilizado con un contenido de g/c aumentado. |
| JP4691495B2 (ja) * | 2004-07-15 | 2011-06-01 | 一般財団法人化学及血清療法研究所 | コロナウイルススパイクｓ１融合蛋白及びその発現ベクター |
| US9012219B2 (en) | 2005-08-23 | 2015-04-21 | The Trustees Of The University Of Pennsylvania | RNA preparations comprising purified modified RNA for reprogramming cells |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| JP2010531640A (ja) | 2007-06-29 | 2010-09-30 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション | 毒性化合物の分解方法 |
| CA2715078C (en) | 2007-09-26 | 2019-07-23 | Intrexon Corporation | Synthetic 5'utrs, expression vectors, and methods for increasing transgene expression |
| SG10201408162PA (en) | 2007-12-11 | 2015-01-29 | Scripps Research Inst | Compositions and methods related to mrna translational enhancer elements |
| RU2013154295A (ru) | 2011-06-08 | 2015-07-20 | Шир Хьюман Дженетик Терапис, Инк. | КОМПОЗИЦИИ ЛИПИДНЫХ НАНОЧАСТИЦ И СПОСОБЫ ДЛЯ ДОСТАВКИ мРНК |
| EP2858679B2 (en) | 2012-06-08 | 2024-06-05 | Translate Bio, Inc. | Pulmonary delivery of mrna to non-lung target cells |
| EP3388834B1 (en) | 2013-03-15 | 2020-04-15 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
| WO2014152027A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Manufacturing methods for production of rna transcripts |
| KR102354389B1 (ko) | 2013-08-21 | 2022-01-20 | 큐어백 아게 | Rna―암호화된 단백질의 발현을 증가시키는 방법 |
| WO2015062738A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Gmbh | Modified rna with decreased immunostimulatory properties |
| CN111304231A (zh) | 2013-12-30 | 2020-06-19 | 库瑞瓦格股份公司 | 人工核酸分子 |
| CA2927254C (en) | 2013-12-30 | 2023-10-24 | Curevac Ag | Artificial nucleic acid molecules |
| PL4023249T3 (pl) * | 2014-04-23 | 2025-03-10 | Modernatx, Inc. | Szczepionki z kwasem nukleinowym |
| JP7384512B2 (ja) * | 2015-10-22 | 2023-11-21 | モデルナティエックス インコーポレイテッド | 広域インフルエンザウイルスワクチン |
| EP4011451A1 (en) * | 2015-10-22 | 2022-06-15 | ModernaTX, Inc. | Metapneumovirus mrna vaccines |
| EP3405579A1 (en) | 2016-01-22 | 2018-11-28 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
| CA3036831A1 (en) | 2016-09-14 | 2018-03-22 | Modernatx, Inc. | High purity rna compositions and methods for preparation thereof |
| WO2019036682A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | RNA VARIANTS POLYMERASE |
| JP2023511633A (ja) * | 2020-01-28 | 2023-03-20 | モデルナティエックス インコーポレイテッド | コロナウイルスｒｎａワクチン |
| KR20220144416A (ko) * | 2020-02-04 | 2022-10-26 | 큐어백 아게 | 코로나바이러스 백신 |
| BR112022015565A2 (pt) * | 2020-02-07 | 2022-09-27 | Modernatx Inc | Vacinas de domínio de mrna para sars-cov-2 |
| CA3176481A1 (en) * | 2020-04-22 | 2021-10-28 | Marjoh NAUTA | Coronavirus vaccine |
| EP4146265A1 (en) * | 2020-05-07 | 2023-03-15 | Translate Bio, Inc. | Optimized nucleotide sequences encoding sars-cov-2 antigens |
-
2022
- 2022-01-14 WO PCT/US2022/012607 patent/WO2022155524A1/en not_active Ceased
- 2022-01-14 US US18/272,512 patent/US20240100151A1/en active Pending
- 2022-01-14 JP JP2023543034A patent/JP2024503698A/ja active Pending
- 2022-01-14 CA CA3208486A patent/CA3208486A1/en active Pending
- 2022-01-14 EP EP22703172.1A patent/EP4277655A1/en active Pending
- 2022-01-14 AU AU2022208057A patent/AU2022208057A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024503698A5 (https=) | ||
| JP2024503699A5 (https=) | ||
| Pardi et al. | mRNA vaccines for infectious diseases—advances, challenges and opportunities | |
| JP2023513073A5 (https=) | ||
| ES3058501T3 (en) | Rsv f protein mutants | |
| ES2869199T3 (es) | Sistemas de expresión | |
| Carragher et al. | A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus | |
| TW199861B (https=) | ||
| JP2006504654A5 (https=) | ||
| JP2023546369A5 (https=) | ||
| Ibañez et al. | M2e-displaying virus-like particles with associated RNA promote T helper 1 type adaptive immunity against influenza A | |
| JP2022533318A (ja) | 気道感染の治療または予防のためのサブユニットワクチン | |
| WO2006136084A1 (en) | Fusion proteins of recombinant sars coronavirus structural proteins, their production and uses | |
| BR112012024872B1 (pt) | Composições farmacêuticas compreendendo um polipeptídeo contendo pelo menos um motivo cxxc e antígenos heterólogos e seus usos | |
| JP2017538672A (ja) | Ｃｍｖ由来改変ウイルス様粒子 | |
| JP2013523887A5 (https=) | ||
| JP2024542635A5 (https=) | ||
| IL298362A (en) | Coronavirus antigen compositions and their uses | |
| JP2009518007A5 (https=) | ||
| JP2010536787A5 (https=) | ||
| JP2010536878A (ja) | インフルエンザタンパク質を製造および使用する組成物および方法 | |
| Ebrahimi et al. | In contrast to conventional inactivated influenza vaccines, 4xM2e. HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran | |
| JP2019088329A5 (https=) | ||
| JP2020519663A (ja) | Ｒｓｖ感染に対する防御免疫を誘導するための方法及び組成物 | |
| FR2726471A1 (fr) | Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins |